The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > May 22, 2025
Daily News
May 22, 2025
- Camzyos, Tremfya, Tivdak, and More Now Available in Japan
May 22, 2025
- Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
May 22, 2025
- MHLW Orders Label Revisions for Diuretics, Zolgensma
May 22, 2025
- LDP Generic League Calls for Necessary Pricing Steps to Ensure Quality and Supply
May 22, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
- Alloy Japan Now Up and Running to Deliver iCAR-T for Cancer Therapy Development
May 22, 2025
- MSD Chief Decries Japan’s Unpredictable Policy Flip, Frets Future Investment
May 22, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…